Drug encapsulation and release from multilamellar and unilamellar liposomes

Betageri, Guru V.; Parsons, Daniel L.

doi:10.1016/0378-5173(92)90015-t

Cited by 78 publications

(46 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…From the results, it is obvious that the increase of cholesterol molar ratio from 1:0.5:0.1 to 1:1:0.1 (non-ionic surfactant: cholesterol: DCP) markedly reduced the efflux of the drug from niosomal preparations (F3, F4, F11 and F12), which is in accordance with its membrane stabilizing ability (40). Cholesterol is known to abolish the gel to liquid phase transition of niosome systems (35), resulting in niosomes that are less leaky (36).…”

Section: Determination Of Vesicle Sizesupporting

confidence: 57%

Niosome-Encapsulated Gentamicin for Ophthalmic Controlled Delivery

2008

View full text Add to dashboard Cite

Abstract. The objective of the present research was to investigate the feasibility of using non-ionic surfactant vesicles (niosomes) as carriers for the ophthalmic controlled delivery of a water soluble local antibiotic; gentamicin sulphate. Niosomal formulations were prepared using various surfactants (Tween 60, Tween 80 or Brij 35), in the presence of cholesterol and a negative charge inducer dicetyl phosphate (DCP) in different molar ratios and by employing a thin film hydration technique. The ability of these vesicles to entrap the studied drug was evaluated by determining the entrapment efficiency %EE after centrifugation and separation of the formed vesicles. Photomicroscopy and transmission electron microscopy as well as particle size analysis were used to study the formation, morphology and size of the drug loaded niosomes. Results showed a substantial change in the release rate and an alteration in the %EE of gentamicin sulphate from niosomal formulations upon varying type of surfactant, cholesterol content and presence or absence of DCP. In-vitro drug release results confirmed that niosomal formulations have exhibited a high retention of gentamicin sulphate inside the vesicles such that their in vitro release was slower compared to the drug solution. A preparation with 1:1:0.1 molar ratio of Tween 60, cholesterol and DCP gave the most advantageous entrapment (92.02%±1.43) and release results (Q 8h =66.29%±1.33) as compared to other compositions. Ocular irritancy test performed on albino rabbits, showed no sign of irritation for all tested niosomal formulations.

show abstract

Section: Determination Of Vesicle Sizesupporting

confidence: 57%

Niosome-Encapsulated Gentamicin for Ophthalmic Controlled Delivery

2008

View full text Add to dashboard Cite

show abstract

“…It was reported that multilamellar vesicles (MLV) have shown barrier property for the release of encapsulated watersoluble drug, e.g. atenolol, and retarded the drug release compared to drug encapsulated in small unilamellar vesicles (SUV) (Betageri & Parsons, 1992). Drug release from MLV has two main points of interests.…”

Section: Introductionmentioning

confidence: 99%

“…First, phospholipid bilayers may simulate some fundamental properties of biological membranes and constitute a model system to investigate passive drug transport. Second, there is a possibility of application of these systems for sustained or controlled drug delivery application, mainly for non-parenteral route of administration (Betageri & Parsons, 1992).…”

Section: Introductionmentioning

confidence: 99%

Controlled release application of multilamellar vesicles: a novel drug delivery approach

2010

View full text Add to dashboard Cite

“…As a result, unilamellar liposomes with a hydrodynamic diameter of 130 nm exhibit a much faster release rate than MLVs with two to three lamellar bilayers and a hydrodynamic diameter of 250 nm. 10,11 The difference in the release rate is due overall to the number of phospholipid bilayer that it have to cross before being released.…”

Section: The Physicochemistry Of Liposomesmentioning

confidence: 99%

Liposomes as nanomedical devices

Bozzuto¹,

Molinari²

2015

IJN

1,735

1,114

View full text Add to dashboard Cite

Since their discovery in the 1960s, liposomes have been studied in depth, and they continue to constitute a field of intense research. Liposomes are valued for their biological and technological advantages, and are considered to be the most successful drug-carrier system known to date. Notable progress has been made, and several biomedical applications of liposomes are either in clinical trials, are about to be put on the market, or have already been approved for public use. In this review, we briefly analyze how the efficacy of liposomes depends on the nature of their components and their size, surface charge, and lipidic organization. Moreover, we discuss the influence of the physicochemical properties of liposomes on their interaction with cells, half-life, ability to enter tissues, and final fate in vivo. Finally, we describe some strategies developed to overcome limitations of the “first-generation” liposomes, and liposome-based drugs on the market and in clinical trials.

show abstract

Drug encapsulation and release from multilamellar and unilamellar liposomes

Cited by 78 publications

References 27 publications

Niosome-Encapsulated Gentamicin for Ophthalmic Controlled Delivery

Niosome-Encapsulated Gentamicin for Ophthalmic Controlled Delivery

Controlled release application of multilamellar vesicles: a novel drug delivery approach

Liposomes as nanomedical devices

Contact Info

Product

Resources

About